Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307470 | 0.86 | CYP3A4 (0.61) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL426773 | 0.86 | HSD17B10 (0.54) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL29383625 | 0.86 | HSD17B10 (0.54) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL137400 | 0.85 | KDM4E (0.56) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4723016 | 0.85 | KDM4E (0.52) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL16293655 | 0.85 | KDM4E (0.52) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2562856 | 0.85 | HSD17B10 (0.61) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14097991 | 0.85 | HSD17B10 (0.57) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7994543 | 0.83 | KDM4E (0.55) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2561912 | 0.83 | KDM4E (0.49) | HSD17B10KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| WO-2025085560-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| EP-1894911-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1894911-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HSD17B10 868/4885KDM4E 3794/4885ALDH1A1 1592/4885 |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | HSD17B10 3086/4885KDM4E 2249/4885ALDH1A1 3028/4885 |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F12, F11, F2 | HSD17B10 1622/4885KDM4E 3040/4885ALDH1A1 262/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HSD17B10 2273/4885KDM4E 3113/4885ALDH1A1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.